Hirotaka Miyashita1,2, Sera Satoi3, Christina Cruz3, Se-Min Kim4,5, Vaibhav G Patel6. 1. Department of Medicine, Icahn School of Medicine At Mount Sinai, Mount Sinai Beth Israel, New York, NY, USA. Hirotaka.Miyashita@mountsinai.org. 2. Mount Sinai Bone Program, Icahn School of Medicine At Mount Sinai, New York, NY, USA. Hirotaka.Miyashita@mountsinai.org. 3. Department of Medicine, Icahn School of Medicine At Mount Sinai, Mount Sinai Beth Israel, New York, NY, USA. 4. Department of Medicine, Icahn School of Medicine At Mount Sinai, Mount Sinai Beth Israel, New York, NY, USA. se-min.kim@mountsinai.org. 5. Mount Sinai Bone Program, Icahn School of Medicine At Mount Sinai, New York, NY, USA. se-min.kim@mountsinai.org. 6. Tisch Cancer Institute, Icahn School of Medicine At Mount Sinai, New York, NY, USA.
Abstract
BACKGROUND: The data of head-to-head comparisons of the effect of bone-modifying agents (BMAs) in patients with androgen deprivation therapy (ADT) for prostate cancer without skeletal metastasis is limited. Thus, we conducted a network meta-analysis to compare each BMA for the efficacy of bone mineral densities (BMDs) and the risk of fracture. METHODS: We performed a network meta-analysis to compare the change of BMDs and the risk of vertebral fracture in the studies included using a random-effect model. The primary outcomes are the change of BMD of the lumbar spine (LS) and the total hip (TH) from the baseline at 1 year from the initiation of the BMA and the risk of vertebral fracture. RESULTS: We identified and included 15 studies in this analysis. All BMAs except risedronate showed a significant increase of BMD of the LS compared with groups without BMA, among which zoledronate showed the most BMD gain. At TH, bisphosphonates (alendronate, pamidronate, and zoledronate) and denosumab showed significant elevation compared with the no-BMA group. Denosumab was associated with the most BMD gain at the TH. Only denosumab reduced the risk of vertebral fracture (relative risk [95% confidence interval]: 0.40 [0.20-0.81]). Although zoledronate showed the highest BMD gain at the LS, it did not reduce the risk of vertebral fracture in this analysis. CONCLUSION: Most bisphosphonates and denosumab significantly increased BMD at the LS and the TH in patients receiving ADT for prostate cancer without skeletal metastasis. In particular, zoledronate and denosumab were the most potent BMAs in terms of BMD increment at the LS and the TH, respectively. However, denosumab, not zoledronate, was the only BMA that showed a significant risk reduction of vertebral fracture. We need further studies to examine the change of bone quality and the effect on the risk of non-vertebral and hip fractures.
BACKGROUND: The data of head-to-head comparisons of the effect of bone-modifying agents (BMAs) in patients with androgen deprivation therapy (ADT) for prostate cancer without skeletal metastasis is limited. Thus, we conducted a network meta-analysis to compare each BMA for the efficacy of bone mineral densities (BMDs) and the risk of fracture. METHODS: We performed a network meta-analysis to compare the change of BMDs and the risk of vertebral fracture in the studies included using a random-effect model. The primary outcomes are the change of BMD of the lumbar spine (LS) and the total hip (TH) from the baseline at 1 year from the initiation of the BMA and the risk of vertebral fracture. RESULTS: We identified and included 15 studies in this analysis. All BMAs except risedronate showed a significant increase of BMD of the LS compared with groups without BMA, among which zoledronate showed the most BMD gain. At TH, bisphosphonates (alendronate, pamidronate, and zoledronate) and denosumab showed significant elevation compared with the no-BMA group. Denosumab was associated with the most BMD gain at the TH. Only denosumab reduced the risk of vertebral fracture (relative risk [95% confidence interval]: 0.40 [0.20-0.81]). Although zoledronate showed the highest BMD gain at the LS, it did not reduce the risk of vertebral fracture in this analysis. CONCLUSION: Most bisphosphonates and denosumab significantly increased BMD at the LS and the TH in patients receiving ADT for prostate cancer without skeletal metastasis. In particular, zoledronate and denosumab were the most potent BMAs in terms of BMD increment at the LS and the TH, respectively. However, denosumab, not zoledronate, was the only BMA that showed a significant risk reduction of vertebral fracture. We need further studies to examine the change of bone quality and the effect on the risk of non-vertebral and hip fractures.
Authors: John A Kanis; Nicholas C Harvey; Helena Johansson; Anders Odén; William D Leslie; Eugene V McCloskey Journal: J Clin Densitom Date: 2017-07-18 Impact factor: 2.617
Authors: Charles L Shapiro; Catherine Van Poznak; Christina Lacchetti; Jeffrey Kirshner; Richard Eastell; Robert Gagel; Sean Smith; Beatrice J Edwards; Elizabeth Frank; Gary H Lyman; Matthew R Smith; Rahul Mhaskar; Tara Henderson; Joan Neuner Journal: J Clin Oncol Date: 2019-09-18 Impact factor: 44.544
Authors: Susan L Greenspan; Penelope Coates; Susan M Sereika; Joel B Nelson; Donald L Trump; Neil M Resnick Journal: J Clin Endocrinol Metab Date: 2005-09-27 Impact factor: 5.958
Authors: Panagiotis Anagnostis; Stavroula A Paschou; Gesthimani Mintziori; Iuliana Ceausu; Herman Depypere; Irene Lambrinoudaki; Alfred Mueck; Faustino R Pérez-López; Margaret Rees; Levent M Senturk; Tommaso Simoncini; John C Stevenson; Petra Stute; Florence A Trémollieres; Dimitrios G Goulis Journal: Maturitas Date: 2017-04-15 Impact factor: 4.342
Authors: Philip Cornford; Joaquim Bellmunt; Michel Bolla; Erik Briers; Maria De Santis; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Thomas Wiegel; Nicolas Mottet Journal: Eur Urol Date: 2016-08-31 Impact factor: 20.096
Authors: M R Smith; F J McGovern; A L Zietman; M A Fallon; D L Hayden; D A Schoenfeld; P W Kantoff; J S Finkelstein Journal: N Engl J Med Date: 2001-09-27 Impact factor: 91.245
Authors: Matthew R Smith; James Eastham; Donald M Gleason; Daniel Shasha; Simon Tchekmedyian; Norman Zinner Journal: J Urol Date: 2003-06 Impact factor: 7.450